STK11 mutation status is associated with decreased survival in meningiomas

ConclusionThese data identify recurrentSTK11 mutations in a subset of meningiomas. Genotyping ofSTK11 is encouraged for meningioma patients undergoing immunotherapy-based therapy.
Source: Neurological Sciences - Category: Neurology Source Type: research

Related Links:

Condition:   Esophageal Malignant Neoplasm, Local Recurrence Interventions:   Drug: Procedural death 1;   Drug: Capecitabine;   Radiation: Radiotherapy;   Drug: Placebo Sponsor:   The First Affiliated Hospital of Henan University of Science and Technology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 26 May 2020Source: Gynecologic Oncology ReportsAuthor(s): John K. Chan, David S. Lakomy, Yassmina McDonald, Daniel S Kapp
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
(University of Pennsylvania School of Medicine) Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions. Reporting in Nature Cancer, the researchers showed for the first time in human cells and a mouse model that inhibiting the c-Rel molecule in myeloid cells -- as opposed to lymphoid cells that today's immunotherapies target -- blocked the production of immune suppressor cells and significantly shrank tumors.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Stereotactic body radiotherapy (SBRT) is an increasingly used radiation modality for the treatment of both localized and metastatic prostate cancer. Substantial data suggests that prostate cancer may be more sensitive to higher doses of radiation per fraction due to its low α/β ratio. This increased sensitivity raises important questions as to how SBRT should be combined with systemic therapy for clinically significant prostate cancer, including whether androgen deprivation therapy retains its beneficial effects when combined with SBRT. Furthermore, pre-clinical and clinical data suggest pronounced immunomodulat...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Background: Although immunotherapy with checkpoint inhibitors is changing the face of lung adenocarcinoma (LUAD) treatments, only limited patients could benefit from it. Therefore, we aimed to develop an immune-relevant-gene-based signature to predict LUAD patients' prognosis and to characterize their tumor microenvironment thus guiding therapeutic strategy.Methods and Materials: Gene expression data of LUAD patients from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) were systematically analyzed. We performed Cox regression and random survival forest algorithm to identify immune-relevant genes with poten...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Therapeutic monoclonal antibodies (mAbs), targeting tumor antigens, or immune checkpoints, have demonstrated a remarkable anti-tumor effect against various malignancies. However, high costs for mono- or combination therapies, associated with adverse effects or possible development of resistance in some patients, warrant further development and modification to gain more flexibility for this immunotherapy approach. An attractive alternative to passive immunization with therapeutic antibodies might be active immunization with mimotopes (B-cell peptides) representing the mAbs' binding epitopes, to activate the patient's own an...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study was to investigate the role of CD40 in HPV16-specific CD8+ Tscm induction and its anti-tumor function. We found that CD40 activation accelerated vaccine-induced HPV16 E7-specific CD8+ Tscm formation. Comparing to other HPV-specific CD8+ T cells, CD8+ Tscm were found to be stronger and long-term anti-tumor function, in vivo and in vitro, even in the adoptive cellular transferring model. Furthermore, high frequencies of Tscm might prevent the HPV infection to move on to the development of cancer. And the CD40 effect on Tscm involved Wnt/β-catenin activation. Our study suggest that CD40 activation supports the...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract Blocking of the interaction between Programmed cell death 1 (PD-1) and its ligand PD-L1 by monoclonal antibodies has elicited unprecedented therapeutic benefits and achieved a major breakthrough in immunotherapy of multiple types of tumors. Here, we determined the crystal structure of PD-1 in complex with the Fab fragment of tislelizumab. This monoclonal antibody was approved in December 2019 by the China National Medical Product Administration for Hodgkin's lymphoma and is under multiple clinical trials in China and the US. While the three complementarity determining regions (CDRs) in the light chain are...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Chem. Soc. Rev., 2020, Advance Article DOI: 10.1039/C9CS00773C, Review ArticleChi Zhang, Kanyi Pu This review summarizes the development of activatable immunotherapeutic nanoagents that activate antitumor immunity only in response to internal or external stimuli, which potentially enhance patient response rates while reducing immune-related adverse events during cancer immunotherapy. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chemical Society Reviews - Category: Chemistry Authors: Source Type: research
Dendritic cells (DCs) play a critical role in mediating innate and adaptive immune responses. Since their discovery in the late 1970's, DCs have been recognized as the most potent antigen-presenting cells (APCs). DCs have a superior capacity for acquiring, processing, and presenting antigens to T cells and they express costimulatory or coinhibitory molecules that determine immune activation or anergy. For these reasons, cell-based therapeutic approaches using DCs have been explored in cancer and infectious diseases but with limited success. In humans, DCs are divided into heterogeneous subsets with distinct characteristics...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Immunotherapy | Men | Neurology